First iPS Cell Trial Underway But A Long Way To Go
This article was originally published in PharmAsia News
Researchers in Japan have "dosed" the initial patient in the world's first clinical trial involving a regenerative therapy based on the country's flagship induced pluripotent stem (iPS) cell technology.
You may also be interested in...
Building on its national expertise in the area, Japan is starting the first clinical trial globally to assess the use of iPS-derived cells for the treatment of Parkinson’s disease.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.